Story perspectives

UCB to Acquire Candid Therapeutics for $2.2 B

5/4/2026

Summary

UCB Acquires Candid

UCB will acquire Candid Therapeutics for up to $2.2 billion.
The transaction includes $2 billion upfront and up to $200 million in milestone payments.
Cizutamig, Candid’s lead bispecific BCMA-CD3 T-cell engager, has been evaluated in more than 100 patients.
The same asset is being studied in over 10 autoimmune indications.
UCB expects the acquisition to close by the end of Q2 or early Q3 2026, subject to antitrust clearance.

Summary

UCB Acquires Candid

Two River and Vida Ventures confirmed UCB’s $2.2 billion acquisition of Candid.
Two River, a New York incubator, co-founded Candid with Third Rock by merging TRC 2004 and Vignette Bio.
Vida Ventures controls $1.8 billion, operates in Los Angeles, Boston, New York and Fort Worth, and backed the 2026 IPOs of Aktis Oncology and Avalyn Pharma.
Arie Belldegrun, Bellco Co-Founder, said the deal shows how science, disciplined building and strategic partners create value.

1 of 2

UCB Acquires Candid

UCB will acquire Candid Therapeutics for up to $2.2 billion.
The transaction includes $2 billion upfront and up to $200 million in milestone payments.
Cizutamig, Candid’s lead bispecific BCMA-CD3 T-cell engager, has been evaluated in more than 100 patients.
The same asset is being studied in over 10 autoimmune indications.
UCB expects the acquisition to close by the end of Q2 or early Q3 2026, subject to antitrust clearance.

1 / 2